Minerva Biotechnologies announced that the FDA has approved their Investigational New Drug (IND) application to conduct clinical trials with huMNC2-CAR22, aka MUC1*-CAR-1XX, for the treatment of metastatic breast cancers.
[Minerva Biotechnologies (Business Wire)]